National Academies Press: OpenBook

Aligning Investments in Therapeutic Development with Therapeutic Need: Closing the Gap (2025)

Chapter: Appendix C: Disclosure of Unavoidable Conflicts of Interest

« Previous: Appendix B: Committee and Staff Biographical Sketches
Suggested Citation:"Appendix C: Disclosure of Unavoidable Conflicts of Interest." National Academies of Sciences, Engineering, and Medicine. 2025. Aligning Investments in Therapeutic Development with Therapeutic Need: Closing the Gap. Washington, DC: The National Academies Press. doi: 10.17226/29157.
×
Page 221
Suggested Citation:"Appendix C: Disclosure of Unavoidable Conflicts of Interest." National Academies of Sciences, Engineering, and Medicine. 2025. Aligning Investments in Therapeutic Development with Therapeutic Need: Closing the Gap. Washington, DC: The National Academies Press. doi: 10.17226/29157.
×
Page 222
Suggested Citation:"Appendix C: Disclosure of Unavoidable Conflicts of Interest." National Academies of Sciences, Engineering, and Medicine. 2025. Aligning Investments in Therapeutic Development with Therapeutic Need: Closing the Gap. Washington, DC: The National Academies Press. doi: 10.17226/29157.
×
Page 223
Suggested Citation:"Appendix C: Disclosure of Unavoidable Conflicts of Interest." National Academies of Sciences, Engineering, and Medicine. 2025. Aligning Investments in Therapeutic Development with Therapeutic Need: Closing the Gap. Washington, DC: The National Academies Press. doi: 10.17226/29157.
×
Page 224

Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

C Disclosure of Unavoidable Conflicts of Interest The conflict-of-interest policy of the National Academies of Sciences, Engineering, and Medicine (https://www.nationalacademies.org/about/ institutional-policies-and-procedures/conflict-of-interest-policies-and-­ procedures) prohibits the appointment of an individual to a committee such as the one that authored this Consensus Study Report if the individual has a conflict of interest that is relevant to the task to be performed. An exception to this prohibition is permitted only if the National Academies determine that the conflict is unavoidable and the conflict is promptly and publicly disclosed. When the committee that authored this report was established, a deter- mination of whether there was a conflict of interest was made for each committee member, given the individual’s circumstances and the task being undertaken by the committee. A determination that an individual has a conflict of interest is not an assessment of that individual’s actual behavior or character or ability to act objectively despite the conflicting interest. Dr. Scott Howell was determined to have a conflict of interest in rela- tion to service on the Committee on Strategies to Better Align Investments in Innovations for Therapeutic Development with Disease Burden and Unmet Needs based on his current role with Blue Line Advisors, LLC, through which he provides ad hoc consulting to companies such as Jazz Pharmaceuticals. He is cofounder of Synapse Sciences, an emerging global drug research network. Dr. Howell owns stock in Novartis and United Health Group. The National Academies has concluded that for the committee to accomplish the tasks for which it was established, its membership must 221

222 ALIGNING INVESTMENTS IN THERAPEUTIC DEVELOPMENT include at least one person with current expertise and experience in how strategic investments are made by large pharmaceutical companies. As described in his biographical summary, owing to Dr. Howell’s experience in market access in the pharmaceutical industry, he understands the stra- tegic investment landscape for commercializing innovative therapeutics to address unmet patient needs and making therapeutics deliverable to patients. The National Academies has determined that the expertise and expe- rience of Dr. Howell is needed for the committee to accomplish the task for which it has been established. The National Academies could not find another available individual with the equivalent expertise and experience who does not have a conflict of interest. Therefore, the National Academies has concluded that the conflict is unavoidable. The National Academies believes that Dr. Howell can serve effectively as a member of the committee and that the committee can produce an objective report, taking into account the composition of the committee, the work to be performed, and the procedures to be followed in completing the study. Dr. Edith Perez was determined to have a conflict of interest in relation to service on the Committee on Strategies to Better Align Investments in Innovations for Therapeutic Development with Disease Burden and Unmet Needs based on her role as chief medical officer at Bolt Biotherapeutics, which develops therapeutics to treat numerous cancers. She is on the board of directors of Artiva Biotherapeutics, an early-stage immunotherapy com- pany, and is a member of the Genentech External Council for Advancing Inclusive Research. Her spouse has stock in Genentech. The National Academies has concluded that for the committee to accomplish the tasks for which it was established, its membership must include at least one person who has relevant current expertise and experi- ence in all phases of therapeutic development and the biopharmaceutical industry. As described in her biographical summary, owing to her current role as chief medical officer and her past roles as a physician, principal investigator, and vice president and head of bio-oncology at Genentech, Dr. Perez has extensive expertise and experience in basic science research and clinical trials and the biopharmaceutical industry launching novel therapies. The National Academies has determined that the expertise and experi- ence of Dr. Perez is needed for the committee to accomplish the task for which it has been established. The National Academies could not find another available individual with the equivalent expertise and experience who does not have a conflict of interest. Therefore, the National Academies has concluded that the conflict is unavoidable. The National Academies believes that Dr. Perez can serve effectively as a member of the committee and that the committee can produce an

APPENDIX C 223 objective report, taking into account the composition of the committee, the work to be performed, and the procedures to be followed in completing the study. In July 2024, Dr. Perez’s role with Bolt Therapeutics changed from chief medical officer to advisor. Mr. David Scheer was determined to have a conflict of interest in rela- tion to service on the Committee on Strategies to Better Align Investments in Innovations for Therapeutic Development with Disease Burden and Unmet Needs based on his current role as advisor for Nektar Therapeutics and Twist Biosciences. He is a board member of companies advancing novel therapeutics for unmet needs, including OrphAI Therapeutics and ­BiologicsMD. He is also cochair of BioCT, a nonprofit focused on promot- ing the growth of the life sciences in Connecticut. The National Academies has concluded that for the committee to accomplish the tasks for which it was established, the committee requires expertise in financial investment, including knowledge about the intricacies of commercialization, invest- ment, and sale of novel therapies. Inherent in this expertise is knowledge about the incentives and regulatory policies that influence innovation and the perceived risks and returns on investment of innovative products. As described in his biographical summary, Mr. Scheer has expertise and expe- rience in financial investment and has deep understanding of the many factors that influence the investment, growth, and sale of companies that translate basic science into novel therapeutics. The National Academies has determined that the expertise and expe- rience of Mr. Scheer is needed for the committee to accomplish the task for which it has been established. The National Academies could not find another available individual with the equivalent expertise and experience who does not have a conflict of interest. Therefore, the National Academies has concluded that the conflict is unavoidable. The National Academies believes that Mr. Scheer can serve effectively as a member of the committee and that the committee can produce an objective report, taking into account the composition of the committee, the work to be performed, and the procedures to be followed in completing the study. In each case, the National Academies determined that the experience and expertise of the individual was needed for the committee to accom- plish the task for which it was established. The National Academies could not find another available individual with the equivalent experience and expertise who did not have a conflict of interest. Therefore, the National ­Academies concluded that the conflict was unavoidable and publicly dis- closed it on its website (www.nationalacademies.org).

Next: Appendix D: IHME Methods »
Aligning Investments in Therapeutic Development with Therapeutic Need: Closing the Gap Get This Book
×
 Aligning Investments in Therapeutic Development with Therapeutic Need: Closing the Gap
Buy Paperback | $29.00
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

The United States is a global leader in biomedical research, generating therapeutic breakthroughs that advance the health of the nation and the world. The public and private sectors contribute to this advancement by funding biomedical research and development. The current level of investment in pharmaceutical development in the United States, while substantial, does not always yield desired health outcomes or meet the needs of patients. Public and private funders face a myriad of challenges that affect their funding decisions and hinder the ability of the drug development system to prioritize disease burden and unmet need - often leaving critical gaps in available treatment options.

To better understand these gaps, Gates Ventures and the Peterson Center on Healthcare asked the National Academies to examine current challenges and offer strategies and recommendations for improvement. The resulting report emphasizes that current research prioritization does not systematically account for disease burden and unmet needs, and describes how a robust, timely, accessible data system is needed. It also explores the ways in which implementing recommended policy changes could deliver better health outcomes.

READ FREE ONLINE

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  6. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  7. ×

    View our suggested citation for this chapter.

    « Back Next »
  8. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!